The global pulmonary arterial hypertension market was valued at US$8.18 billion in 2022. The market value is expected to reach US$11.43 billion by 2028. Pulmonary arterial hypertension (PAH) is a rare and progressive disorder characterized by elevated blood pressure of more than 25mmHg in the arteries of the lungs, also known as the pulmonary artery. While PAH affects both genders, it is more prevalent among females aged 30-60 years. Unfortunately, there is no known cure for PAH, but various treatment options are available to manage symptoms and enhance patients' quality of life.

The prevalence of PAH has been increasing over the years, which is contributing to the market growth. It is estimated that 37,000 patients are suffering from PAH in the US in 2022, and a similar number outside the US. Females are more likely to develop PAH, with a female-to-male ratio of 3:1. There are multiple approved drugs to treat PAH, but all are focused on improving hemodynamics in patients and not treating the underlying disease. New drug candidates target novel pathways that look to address the cause of the disease. On the other hand, therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. The development of new and improved therapies for PAH has expanded treatment options and improved patient management. Also, there have been advancements in the understanding of the underlying mechanisms of PAH, leading to the development of targeted therapies that provide better symptom control and disease management. The market is expected to grow at a CAGR of approx. 6% during the forecasted period of 2023-2028.


Scope of the Report:

The report titled “Global Pulmonary Arterial Hypertension (PAH) Market: Analysis By Drug Class (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), sGC Stimulators, and pde-5 Inhibitors), By Type (Branded and Generic), By Route of Administration (Oral, Intravenous/ Subcutaneous, and Inhalation), By Distribution Channel (Hospital Pharmacies and Clinic, Retail Pharmacies, and Online Pharmacies), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028”, includes :
-- An in-depth analysis of the global pulmonary arterial hypertension market by value, by drug class, by type, by route of administration, by distribution channel, by region, etc.

-- The regional analysis of the pulmonary arterial hypertension market, including the following regions:

North America (The US, Canada, and Mexico)
Europe (The UK, Germany, France, Italy, Spain, and Rest of Europe)
Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of the Asia Pacific)
Latin America
Middle East & Africa

-- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

-- Provides an analysis of the COVID-19 impact on the global pulmonary arterial hypertension market.

-- Assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall the pulmonary arterial hypertension market has also been forecasted for the period 2023-2028, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

-- Evaluation of the potential role of the pulmonary arterial hypertension to improve the market status.

-- Identification of new technological developments, R&D activities, and product launches occuring in the pulmonary arterial hypertension market.

-- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

-- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

-- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.


For further details, kindly visit :

https://www.daedal-research.com/pharma-healthcare/global-pulmonary-arterial-hypertension-pah-market-size-and-trends-with-impact-of-covid-19-and-forecast-up-to-2028

Rajeev Kumar
(Business Development Manager)
Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Mobile: +91-9811715635
Tel: +91-120-4553017
Mail ID - [email protected]